Digestive health

Updated 04 July 2014

New vaccine for typhoid fever

An Indian pharmaceutical company has developed the world's first clinically proven typhoid vaccine, giving long-term protection to infants and adults.

Indian pharmaceutical company Bharat Biotech says it has developed the world's first clinically proven typhoid vaccine giving long-term protection to infants and adults.

Typhoid fever causes between 250 000 and 600 000 deaths a year and makes 20 million people a year ill. Around 90% of typhoid deaths occur in Asia and the disease occurs mainly in children under age five, the World Health Organization says.

It is caused by Salmonella Typhi, a highly virulent and invasive bacterium, which is transmitted through food or drink contaminated by the faeces or urine of infected people.

"Bharat Biotech's Typbar-TCV(TM) (vaccine) induces 'T' cell dependent response with much higher antibody levels providing a very high rate of immunity," Bharat Biotech Chairman and Managing Director Krishna M. Ella said in a statement on Monday.

Long-term protection

"We hope this vaccine will reach millions of people and help reduce the burden of this devastating disease in infants and children. "The Hyderabad-based company said this was the world's first clinically proven fourth generation vaccine, providing long-term protection against typhoid to adults and infants of six months and older.

It said currently available typhoid vaccines fell short in two major areas, namely long-term protection and protection for children below two years of age.

"Typhoid fever remains an important public health challenge in many countries of the world. At present, fundamental prevention strategies like improved sanitation, good hygienic practices and access to clean water are still out of reach for many impoverished communities," said Dr Christian Loucq, director-general of the International Vaccine Institute.

"One of the most cost-effective approaches to prevent infectious diseases are vaccines which are available now and could help control the disease, resulting in reduction of unnecessary suffering and adverse financial consequences.

"Bharat Biotech said it had begun commercial production of the vaccine in pre-filled syringes and would produce 10 million doses a year, expandable to 50 million doses in the future, which would be available globally.

Reuters

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Add your comment
Comment 0 characters remaining

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules